Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MDT
STRONG BUYAPPROVEMedtronic plc · Healthcare · Ireland · $106.5B · Avg Vol: $714M/d
Medtronic clears the calibrated bar. All three legs are above the floor (Q64 V57 M53) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q64 is the strongest part of the case.
COMPANY DESCRIPTION
Medtronic plc is a global leader in medical technology, developing, manufacturing, and marketing a broad portfolio of medical devices and therapies for various chronic diseases, including cardiovascular, diabetes, and surgical solutions. The company maintains a strong competitive advantage through its extensive intellectual property, robust R&D pipeline, and deep clinical relationships, driving innovation in patient care worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 31.2B | 32.4B | 33.5B | 36.4B | 5.2% | 36.4B | 38.9B | 40.2B | 5.2% |
| EPS | 3.75 | 2.83 | 2.77 | 3.63 | 3.75 | 0.0% | 3.73 | 4.03 | 4.34 | 7.6% |
| Shares | — | 1.3B | 1.3B | 1.3B | 1.3B | -3.8% | 1.3B | — | — | — |
| Debt | — | 24.4B | 25.0B | 28.5B | 28.0B | 4.7% | 29.1B | — | — | — |
| Equity | — | 51.5B | 50.2B | 48.0B | 49.5B | -1.3% | — | — | — | — |
| Op CF | — | 6.0B | 6.8B | 7.0B | 7.3B | 6.7% | 7.3B | — | — | — |
| Inv CF | — | -3.5B | -2.4B | -1.9B | -2.9B | — | — | — | — | — |
| Fin CF | — | -5.0B | -4.5B | -4.4B | -4.8B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDT | Medtronic plc(you) | $106.5B | 84 | STRONG BUY |
| SYK | Stryker Corporation | $126.6B | 67 | BUY |
| ABL.DE | Abbott Laboratories | $164.9B | 70 | BUY |
| EW | Edwards Lifesciences Corporation | $47.6B | 72 | BUY |
| DXCM | DexCom, Inc. | $27.6B | 83 | STRONG BUY |
| BSX.MX | Boston Scientific Corporation | $66.0B | 63 | HOLD |
| PHIA.AS | Koninklijke Philips N.V. | $26.4B | 87 | STRONG BUY |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
| ZBH | Zimmer Biomet Holdings, Inc. | $17.7B | 91 | STRONG BUY |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 67 | BUY |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.0%